TOVX Theriva Biologics, Inc.
Company Updates ·
The NYSE American company reported $11.3 million of cash at June 30, 2026, after first patients were dosed in a Phase 2a trial of more frequent VCN-01 dosing in pancreatic cancer.
The Phase 2a study will test more frequent repeated dosing of VCN-01 with standard chemotherapy in first-line metastatic pancreatic cancer.
Spain's AEMPS cleared the Phase 2a study of more frequent VCN-01 dosing in first-line metastatic pancreatic cancer.
Clinical Cancer Research published the Phase 1 study of VCN-01 with durvalumab in patients whose cancer was refractory to immunotherapy.
Too few shares were present for the June 5, 2026 special meeting on share issuance for warrants, and the company must call another meeting.
The company reported cash of $14.4 million at March 31, 2026, a runway into Q1 2027, and FDA general agreement on a pivotal Phase 3 design for VCN-01.
A poster on April 20, 2026 will report tumor response, biomarker and subgroup analyses from the VIRAGE Phase 2b trial of VCN-01.
A special meeting on share issuance for warrants did not convene because too few shares were present, and the company will call another meeting.
Theriva says cutting about seven employees, or 32% of its global workforce, and other cost cuts extend its cash runway into the second quarter of 2026. Its 2024 annual report carried a going-concern warning, and the company reported $11.6 million of cash and equivalents at December 31, 2024.
Theriva Biologics filed to sell up to $2,534,352 of stock through A.G.P./Alliance Global Partners, under a cap set by its public float. Its auditor's report carries a going-concern paragraph, and the main survival result in its lead trial has a p-value of 0.0546.
Theriva Biologics, Inc. describes itself as a diversified clinical-stage company developing therapeutics to treat cancer and related diseases. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), is a clinical stage oncolytic human adenovirus modified for tumor-selective replication and to express the enzyme PH20 hyaluronidase. The company acquired VCN Biosciences, S.L. in March 2022 and moved its strategic focus to oncology. VCN-01 has been evaluated in a Phase 2b study for pancreatic cancer, called VIRAGE, and in a Phase 1 study for retinoblastoma, as well as in other Phase 1 studies for solid tumors including head and neck squamous cell carcinoma. Before the acquisition, the company focused on gastrointestinal diseases with SYN-004 (ribaxamase), designed to degrade certain intravenous beta-lactam antibiotics within the GI tract, and SYN-020, a recombinant oral formulation of intestinal alkaline phosphatase. In February 2026 the company entered into a license agreement with Rasayana Therapeutics, Inc., granting an exclusive worldwide license.
| Product or program | What it is | Stage |
|---|---|---|
| VCN-01 (zabilugene almadenorepvec) | Oncolytic adenovirus for solid tumors that expresses PH20 hyaluronidase | Clinical stage; evaluated in Phase 2b for pancreatic cancer |
| SYN-004 (ribaxamase) | Degrades certain IV beta-lactam antibiotics in the GI tract | Clinical development candidate (former GI focus) |
| SYN-020 | Recombinant oral formulation of intestinal alkaline phosphatase | Clinical development candidate (former GI focus) |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $8.6 million | $12.0 million |
| Cash from operations | -$16.7 million | -$16.9 million |
| Cash and equivalents | $13.1 million | $11.6 million |
Our latest story on this, dated Oct 2, 2025: "Theriva Biologics cuts 32% of workforce, expects cash runway into second quarter of 2026". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jun 20, 2025: "Theriva Biologics files to sell up to $2,534,352 of stock through at-the-market program". The story links the filing or release it is based on. Read the story.
Theriva Biologics, Inc. trades under the ticker TOVX on AMEX.
Theriva Biologics, Inc. is listed on AMEX.
The SEC Central Index Key (CIK) for Theriva Biologics, Inc. is 894158. Its filings are on SEC EDGAR.
45,892,668 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-11.
Our directory records Theriva Biologics, Inc. under United States.
Our directory classifies Theriva Biologics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Theriva Biologics, Inc. is US87164U5083.
aibio.space lists Theriva Biologics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as NV.
Theriva Biologics, Inc. describes itself as a diversified clinical-stage company developing therapeutics to treat cancer and related diseases. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), is a clinical stage oncolytic human adenovirus modified for tumor-selective replication and to express the enzyme PH20 hyaluronidase.
VCN-01 (zabilugene almadenorepvec): Oncolytic adenovirus for solid tumors that expresses PH20 hyaluronidase Stage: Clinical stage; evaluated in Phase 2b for pancreatic cancer.
SYN-004 (ribaxamase): Degrades certain IV beta-lactam antibiotics in the GI tract Stage: Clinical development candidate (former GI focus).
$8.6 million in the fiscal year ended Dec 31, 2025, per its annual report.
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a financing. SEC Form 424B5. Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05). Source
Reported a financing. SEC Form 424B5. Source
Reported a financing. SEC Form 424B5. Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.03,5.07,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio